An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Brivaracetam Tablets Ph. Eur. 100 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Briviact (brivaracetam) 100 mg film-coated tablets, Marketing Authorisation Holder: UCB Pharma S.A., Allée de la Recherche 60, B-1070 Bruxelles, Belgium; Manufactured by UCB Pharma S.A., Chemin du Foriest, B-1420 Braine-l’Alleud, Belgium, in healthy adult, human subjects under fasting condition.

2024-516500-42-00 Protocol BRIVA-10-24 Human pharmacology (Phase I) - Bioequivalence study Ended

Start 13 Mar 2025 · End 10 Apr 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol BRIVA-10-24

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Bioequivalence study
Status Ended
Participants planned 36
Countries 1
Sites 1

Epilepsy

Key facts

Sponsor
Sun Pharmaceutical Industries Limited
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nervous System Diseases [C10]
Trial duration
13 Mar 2025 → 10 Apr 2025
Decision date (initial)
2024-12-16
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Epilepsy

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Sun Pharmaceutical Industries Limited

Sponsor organisation
Sun Pharmaceutical Industries Limited
Address
1 Plot No 201 B, Western Express Highway, Goregaon East Western Express Highway Goregaon East
City
Mumbai
Postcode
400063
Country
India

Scientific contact point

Organisation
Sun Pharmaceutical Industries Limited
Contact name
Arshad Khuroo

Public contact point

Organisation
Sun Pharmaceutical Industries Limited
Contact name
Arshad Khuroo

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Romania Ended 36 1
Rest of world 0

Investigational sites

Romania

1 site · Ended
Terapia S.A.
Clinical Pharmacology and Pharmacokinetics, Strada Fabricii Nr 124, 400640, Cluj-Napoca

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Romania 2025-03-13 2025-04-10 2025-03-19 2025-03-28

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-08-30 Romania Acceptable
2024-12-09
2024-12-16